Lytix Biopharma AS (OSL:LYTIX)

Market Cap	382.27M
Revenue (ttm)	11.13M
Net Income (ttm)	-94.27M
Shares Out	68.26M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,012
Average Volume	20,782
Open	5.44
Previous Close	5.36
Day's Range	5.44 - 5.60
52-Week Range	4.55 - 15.00
Beta	-0.60
RSI	60.63
Earnings Date	May 15, 2025

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 8
• Stock Exchange: Oslo Børs
• Ticker Symbol: LYTIX

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.